- Conditions
- Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
- Interventions
- Absorb BVS, XIENCE
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,008 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 190
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 145 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1177–1197
of 1,197
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Parkinson's Disease
- Interventions
- creatine, placebo
- Drug · Other
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- Not listed
- Enrollment
- 1,741 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 40 more
- Conditions
- Vaso-occlusive Crisis, Sickle Cell Disease
- Interventions
- Saline, MST-188
- Drug
- Lead sponsor
- Mast Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years to 65 Years
- Enrollment
- 388 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 50
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Oakland, California + 43 more
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
- Interventions
- Bevacizumab, Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Placebo, Quality-of-Life Assessment
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,873 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 614
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 395 more
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
- Interventions
- Inhaled Treprostinil
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 91
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 67 more
- Conditions
- Metastasis Spine, Metastasis to Bone
- Interventions
- OsteoCool™ RF Ablation
- Device
- Lead sponsor
- MedtronicNeuro
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Fullerton, California • Tampa, Florida + 9 more
- Conditions
- Leukemia
- Interventions
- Quizartinib, Placebo, Chemotherapy
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 52
- States / cities
- Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 43 more
- Conditions
- Epilepsies, Myoclonic
- Interventions
- Placebo, Lorcaserin
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 20 more
- Conditions
- Postoperative Pain
- Interventions
- Hydromorphone
- Drug
- Lead sponsor
- Purdue Pharma LP
- Industry
- Eligibility
- 28 Days to 16 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 14
- States / cities
- Little Rock, Arkansas • Orange, California • Stanford, California + 10 more
- Conditions
- Leukemia
- Interventions
- rituximab, fludarabine phosphate
- Biological · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2010
- U.S. locations
- 34
- States / cities
- La Jolla, California • San Francisco, California • Wilmington, Delaware + 24 more
- Conditions
- Aortic Aneurysm, Thoracic
- Interventions
- Valiant Evo Thoracic Stent Graft System
- Device
- Lead sponsor
- Medtronic Cardiovascular
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Stanford, California • Washington D.C., District of Columbia + 17 more
- Conditions
- Bipolar I Depression
- Interventions
- RG2417, Placebo
- Drug
- Lead sponsor
- Repligen Corporation
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 33 more
- Conditions
- Kidney Neoplasms
- Interventions
- Axitinib (AG-013736), Sorafenib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 723 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 161
- States / cities
- Burbank, California • Downey, California • Glendale, California + 103 more
- Conditions
- Hearing Loss, Unilateral, Cochlear Implants, Hearing Loss, Sensorineural, Single-Sided Deafness (SSD), Asymmetric Hearing Loss
- Interventions
- Programming of cochlear implant audio processor frequency settings
- Device
- Lead sponsor
- Med-El Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 6
- States / cities
- Iowa City, Iowa • Kansas City, Kansas • Chapel Hill, North Carolina + 3 more
- Conditions
- Ovarian Cancer
- Interventions
- carboplatin, paclitaxel
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Up to 120 Years · Female only
- Enrollment
- 571 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 144
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 112 more
- Conditions
- Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
- Interventions
- Eplontersen
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 46
- States / cities
- Scottsdale, Arizona • Beverly Hills, California • La Jolla, California + 35 more
- Conditions
- Stage II Prostate Adenocarcinoma AJCC v7
- Interventions
- Intensity-Modulated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
- Radiation · Other
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 698 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 276
- States / cities
- Mobile, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 230 more
- Conditions
- Breast Cancer, Menopausal Symptoms
- Interventions
- tamoxifen citrate, gene expression analysis, pharmacogenomic studies, questionnaire administration, quality-of-life assessment
- Drug · Genetic · Other + 1 more
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 21 Years to 120 Years · Female only
- Enrollment
- 501 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 7
- States / cities
- Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 4 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- everolimus, sunitinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 471 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 31 more
- Conditions
- Prostate Cancer, Prostatic Neoplasms
- Interventions
- 64Cu-SAR-bisPSMA
- Drug
- Lead sponsor
- Clarity Pharmaceuticals Ltd
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 383 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 23 more
- Conditions
- Lung Cancer
- Interventions
- gemcitabine hydrochloride, irinotecan hydrochloride
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2008
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 31 more